GlassScriptPhysician profile
Sumana Ketha
NPI 1962447805
$3,356.67
in general payments reported to CMS, 2019-2025
30 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $84.33 · 2021: $328 · 2022: $326 · 2023: $725 · 2024: $907 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073 · Entertainment: $70.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,072.93 |
| Entertainment | $70.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $474.21 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.22 | 2021-2025 | Jardiance, Ofev, Tradjenta |
| Shire North American Group INC | $350.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $322.83 | 2021-2025 | |
| Lilly USA, LLC | $239.04 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $229.92 | 2020-2023 | Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $188.00 | 2024-2025 | Caplyta |
| Pfizer INC. | $156.10 | 2023-2025 | |
| Novo Nordisk INC | $139.77 | 2022-2025 | Ozempic, Rybelsus |
| Organogenesis INC. | $124.85 | 2021 | |
| Abbott Laboratories | $122.70 | 2021-2024 | Eterna, Freestyle Libre 3 |
| Astellas Pharma US INC | $116.18 | 2019-2025 | Veozah |
| Optos, INC. | $70.65 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Otsuka America Pharmaceutical, INC. | $48.71 | 2024-2025 | Rexulti |
| Medtronic, INC. | $36.21 | 2024 | Kyphon Express II Kyphopak Tray |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $35.52 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Scilex Pharmaceuticals INC. | $30.37 | 2021 | |
| Mdd US Operations, LLC | $25.86 | 2019 | |
| Dexcom, INC. | $23.83 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $22.92 | 2021 | |
| Redhill Biopharma INC. | $20.35 | 2020 | |
| Sanofi-Aventis U.S. LLC | $20.08 | 2025 | |
| Smith+Nephew, INC. | $19.81 | 2021 | |
| Exact Sciences Corporation | $17.31 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.00 | 2019 | |
| Lundbeck LLC | $15.88 | 2025 | Rexulti |
| Linus Health, INC. | $15.71 | 2023 | |
| Genentech USA, INC. | $15.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.25 | 2019 | |
| Depuy Synthes Sales INC. | $15.01 | 2024 | Orthovisc, Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumana Ketha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.